0001193125-24-024136.txt : 20240205 0001193125-24-024136.hdr.sgml : 20240205 20240205165307 ACCESSION NUMBER: 0001193125-24-024136 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240205 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cano Health, Inc. CENTRAL INDEX KEY: 0001800682 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39289 FILM NUMBER: 24596516 BUSINESS ADDRESS: STREET 1: 9725 NW 117TH AVENUE, SUITE 200 CITY: MIAMI STATE: FL ZIP: 33178 BUSINESS PHONE: 2034227700 MAIL ADDRESS: STREET 1: 9725 NW 117TH AVENUE, SUITE 200 CITY: MIAMI STATE: FL ZIP: 33178 FORMER COMPANY: FORMER CONFORMED NAME: Jaws Acquisition Corp. DATE OF NAME CHANGE: 20200121 8-K 1 d768645d8k.htm FORM 8-K Form 8-K
0001800682 false 0001800682 2024-02-05 2024-02-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 5, 2024 (February 5, 2024)

 

 

 

LOGO

Cano Health, Inc.

(Exact name of registrant as specified in its charter)

 

 

Commission File Number: 001-39289

 

Delaware   98-1524224

(State or other jurisdiction of

incorporation or organization)

  

(IRS Employer

Identification No.)

 

9725 NW 117th Avenue, Miami, FL   33178
(Address of principal executive offices)   (Zip Code)

(855) 226-6633

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Class A common stock, $0.01 par value per share   CANO*   The New York Stock Exchange*

 

*

On February 5, 2024, the New York Stock Exchange determined to commence proceedings to delist and immediately suspended trading in Cano Health, Inc.’s Class A common stock, par value $0.01 per share.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On February 5, 2024, the New York Stock Exchange (the “NYSE”) notified (the “Notice”) Cano Health, Inc. (the “Company”) that the NYSE had determined to (a) commence proceedings to delist the Company’s Class A common stock, par value $0.01 per share (“Common Stock”) and (b) immediately suspend trading in the Company’s Common Stock pursuant to Section 802.01D of the NYSE Listed Company Manual after the Company filed voluntary petitions for relief under Chapter 11 of title 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on February 4, 2024.

The NYSE will apply to the U.S. Securities and Exchange Commission to delist the Company’s Common Stock upon completion of all applicable procedures. The Company does not intend to appeal the NYSE’s determination and therefore expects that its Common Stock will be delisted from the NYSE.

The Common Stock is expected to continue trading on the OTC market under the symbol “CANOQ.”

Item 7.01. Regulation FD Disclosure.

On February 5, 2024, the Company issued a press release regarding the receipt of the Notice from the NYSE. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

Cautionary Note Regarding the Company’s Securities

The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 proceedings is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Chapter 11 proceedings. Holders of shares of the Company’s Common Stock could experience a complete loss on their investment, depending on the outcome of the Chapter 11 proceedings.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

 

Exhibit Number    Description
99.1    Press release dated February 5, 2024.
104    Cover Page Interactive Data file (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

      CANO HEALTH, INC.
February 5, 2024     By:  

/s/ Mark Kent

      Mark Kent
      Chief Executive Officer
 EX-99.1 2 d768645dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

NYSE Suspends Trading in Cano Health, Inc. (CANO) and Commences Delisting Proceedings

MIAMI, FL, February 5, 2024 /PRNewswire/— Cano Health, Inc. (NYSE: CANO) (“Cano Health” or the “Company”) announced today that on February 5, 2024, the New York Stock Exchange (the “NYSE”) notified the Company that the NYSE had determined to (a) commence proceedings to delist the Company’s Class A common stock, par value $0.01 per share (“Common Stock”) and (b) immediately suspend trading in the Company’s Common Stock pursuant to Section 802.01D of the NYSE Listed Company Manual after the Company filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on February 4, 2024.

The NYSE will apply to the U.S. Securities and Exchange Commission to delist the Company’s Common Stock upon completion of all applicable procedures. The Company does not intend to appeal the NYSE’s determination and therefore expects that its Common Stock will be delisted from the NYSE.

The Common Stock is expected to continue trading on the OTC market under the symbol “CANOQ.”

About Cano Health: Cano Health (NYSE: CANO) is a high-touch, technology-powered healthcare company delivering personalized, value-based primary care to approximately 310,000 members. Founded in 2009, with its headquarters in Miami, Florida, Cano Health is transforming healthcare by delivering primary care that measurably improves the health, wellness, and quality of life of its patients and the communities it serves through its primary care medical centers and supporting affiliated providers. For more information, visit canohealth.com or investors.canohealth.com.

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to future events and involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and could materially affect actual results, performance or achievements. These forward-looking statements generally can be identified by words such as “will,” “shall,” “may,” “expects,” “anticipates,” “believes,” “foresees,” “forecasts,” “plans,” “seeks,” “intends,” “estimates” or other words or phrases of similar import, including, without limitation, statements regarding: (i) the Company’s Chapter 11 proceedings; and (ii) the Company’s Common Stock trading on the OTC market and the timing thereof. It is uncertain whether any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what impact they will have on our results of operations and financial condition. Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, changes in market or industry conditions, the regulatory environment, competitive conditions, and/or consumer receptivity to our services; changes in our strategy, future operations, prospects and plans; our ability to realize expected financial results, including with respect to patient membership, total revenue and earnings; our ability to predict and control our medical cost ratio; our ability to maintain our relationships with health plans and other key payors; our future capital requirements and sources and uses of cash, including funds to satisfy our liquidity needs; our ability to attract and retain members of management and our Board of Directors; and/or our ability to recruit and retain qualified team members and independent physicians. Actual results may also differ materially from such forward-looking statements for a number of other reasons, including

those set forth in our filings with the SEC, including, without limitation, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 15, 2023, as amended by our Annual Report on Form 10-K/A, filed with the SEC on April 7, 2023 (the “2022 Form 10-K”), and our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we have filed or will file with the SEC during 2023 and 2024 (which may be viewed on the SEC’s website at http://www.sec.gov or on our website at http://www.investors.canohealth.com/ir-home), as well as reasons including, without limitation, our experiencing delays or difficulties in, and/or unexpected or less than anticipated results from its efforts to (i) successfully pursue the Chapter 11 proceedings; and/or (ii) unexpected changes impacting the trading of the Company’s Common Stock. For a detailed discussion of other risks and uncertainties that could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, please refer to our filings with the SEC, including, without limitation, our 2022 Form 10-K and our SEC filings noted above. Factors other than those listed above could also cause our results to differ materially from expected results. Forward-looking statements speak only as of the date they are made and, except as required by law, we undertake no obligation or duty to publicly update or revise any forward-looking statement, whether to reflect actual results of operations; changes in financial condition; changes in general U.S. or international economic, industry conditions; changes in estimates, expectations or assumptions; or other circumstances, conditions, developments or events arising after the issuance of this press release. Additionally, the business and financial materials and any other statement or disclosure on or made available through the Company’s websites or other websites referenced herein shall not be incorporated by reference into this press release.

The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 proceedings is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Chapter 11 proceedings. Holders of shares of the Company’s Common Stock could experience a complete loss on their investment, depending on the outcome of the Chapter 11 proceedings.

Media Contacts

David Zarco

mediarelations@canohealth.com

Kekst CNC

Ruth Pachman / Nicholas Capuano

ruth.pachman@kekstcnc.com / nicholas.capuano@kekstcnc.com

Investor Contact

Cano Health IR

investors@canohealth.com

EX-101.SCH 3 cano-20240205.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cano-20240205_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Incorporation State Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 1 Entity Address City Or Town Entity Address City Or Town Entity Address State Or Province Entity Address State Or Province Entity Address Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 5 cano-20240205_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g768645g0206020524915.jpg GRAPHIC begin 644 g768645g0206020524915.jpg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end GRAPHIC 7 g768645g0206020525034.jpg GRAPHIC begin 644 g768645g0206020525034.jpg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htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information
Feb. 05, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 05, 2024
Entity Registrant Name Cano Health, Inc
Entity File Number 001-39289
Entity Incorporation State Country Code DE
Entity Tax Identification Number 98-1524224
Entity Address Address Line 1 9725 NW 117th Avenue
Entity Address City Or Town Miami
Entity Address State Or Province FL
Entity Address Postal Zip Code 33178
City Area Code 855
Local Phone Number 226-6633
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Class A common stock, $0.01 par value per share
Trading Symbol CANO
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0001800682
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000001 - Document - Document and Entity Information Sheet http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports cano-20240205.xsd cano-20240205_lab.xml cano-20240205_pre.xml d768645d8k.htm g768645g0206020524915.jpg http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d768645d8k.htm": { "nsprefix": "cano", "nsuri": "http://www.canohealth.com/20240205", "dts": { "schema": { "local": [ "cano-20240205.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "cano-20240205_lab.xml" ] }, "presentationLink": { "local": [ "cano-20240205_pre.xml" ] }, "inline": { "local": [ "d768645d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-05_to_2024-02-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d768645d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-05_to_2024-02-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d768645d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "terseLabel": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "terseLabel": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.canohealth.com//20240205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001193125-24-024136-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-024136-xbrl.zip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
  •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d768645d8k_htm.xml IDEA: XBRL DOCUMENT 0001800682 2024-02-05 2024-02-05 0001800682 false 8-K 2024-02-05 Cano Health, Inc 001-39289 DE 98-1524224 9725 NW 117th Avenue Miami FL 33178 855 226-6633 false false false false Class A common stock, $0.01 par value per share CANO NYSE false